Figure 1.

Anti-TNF-α antibody and lactoferrin inhibit oxazolone-, but not DNCB-induced LC migration. Mice (BALB/c) received (a) intradermal injections of anti-TNF-α antibody (or normal rabbit serum [NRS] control) or (b) topical application of human LF in aqueous cream (0·5 μg) (or aqueous cream alone control) to the dorsum of both ears. After 2 hr, mice received a topical application of 0·5% oxazolone (Ox) or 1% DNCB at the same site. Naïve control mice remained untreated. After a further 4 hr epidermal sheets were prepared and stained for LC using FITC-conjugated MHC class II antibody. (a) and (b) LC frequency expressed as mean LC/mm² per group ± SEM (Each graph represents one individual experiment, n = 6 ears). The significance of differences between treated groups and naïve controls was analyzed by a one-way anova followed by Tukey's post-test (**P < 0·01). Representative micrographs of epidermal sheets from (c) naïve (untreated), (d) NRS/Ox, (e) anti-TNF-α/Ox, (f) NRS/DNCB, and (g) anti-TNF-α/DNCB; scale bar = 50 μm.